Summary

Obesity drugs have eluded the United States Food and Drug Administration (FDA) approval process for 13 years, but with mechanisms of action identified and obesity recognized as a disease, that is changing. This article reviews the history of obesity pharmacology, present options in obesity pharmacotherapy, as well as the discovery of peptide-based mixed agonists based on glucagon.